Therapeutic gene modulation

Vividion Appoints Patty Allen, Experienced Financial Executive, as Acting Chief Financial Officer

Retrieved on: 
Thursday, January 7, 2021
Oncology, Health, Infectious diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Life sciences, Alnylam Pharmaceuticals, Therapeutic gene modulation, Biotechnology, Alkermes, Industry economics)

Vividion Therapeutics, Inc., a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that seasoned financial executive Patricia Patty Allen has joined Vividion as acting chief financial officer.

Key Points: 
  • Vividion Therapeutics, Inc., a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that seasoned financial executive Patricia Patty Allen has joined Vividion as acting chief financial officer.
  • Patty is a highly accomplished industry veteran with deep financial leadership expertise, having led financial functions for both large and small organizations through periods of pivotal growth, said Jeffrey Hatfield, chief executive officer of Vividion.
  • Im excited to partner with the team to help build a strong financial organization that will support the companys continued execution and future success.
  • Earlier, she served in financial related roles of increasing responsibility across the biotechnology industry, including at Alnylam, Alkermes and Zafgen.

Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 4, 2021
Infectious diseases, General Health, Pharmaceutical, Health, Alnylam Pharmaceuticals, Therapeutic gene modulation, Biotechnology, Breakout, NASDAQ, Life sciences, Companies

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 am ET.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 am ET.
  • This presentation will include an update on unaudited fourth quarter and full year 2020 global net product revenues.
  • In addition, the Company will webcast the Q&A breakout session immediately following its presentation at 8:40 am ET.
  • A live audio webcast of both the presentation and breakout session will be available on the Investors section of the Companys website, www.alnylam.com/events .

Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders

Retrieved on: 
Monday, December 21, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Food and drink, Cuisine, Foods, Alnylam Pharmaceuticals, Therapeutic gene modulation, Kasha, Tolga, Regulatory compliance

After an in-depth and comprehensive search, we have selected Tolga Tanguler, a dynamic and highly skilled commercial leader to join Alnylam.

Key Points: 
  • After an in-depth and comprehensive search, we have selected Tolga Tanguler, a dynamic and highly skilled commercial leader to join Alnylam.
  • With Tolga, Kasha, Salil and Aggie joining Alnylam, we have now rounded out our world-class leadership team across our commercial, medical and compliance expertise areas.
  • Salil brings a wealth of experience in global Medical Affairs, working with cross-functional teams in Commercial, Market Access as well as R&D.
  • Agnieszka (Aggie) Gallagher joined Alnylam in June 2020 as Chief Ethics and Compliance Officer.

Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation

Retrieved on: 
Thursday, December 17, 2020
Ionis, Antisense RNA, Therapeutic gene modulation, Spinal muscular atrophy, Ionis Pharmaceuticals

Dr. Crooke is stepping down so that he may focus on his scientific interests and the nonprofit organization he founded, the n-Lorem Foundation.

Key Points: 
  • Dr. Crooke is stepping down so that he may focus on his scientific interests and the nonprofit organization he founded, the n-Lorem Foundation.
  • Dr. Crooke will continue to serve as a scientific advisor to Ionis including providing advice regarding Ionis' research and development programs and guiding the core antisense research group he founded at Ionis.
  • Dr. Crooke founded Ionis more than 30 years ago and is credited with being the pioneer of RNA-targeted therapeutics.
  • Under his leadership, Ionis developed its novel antisense technology and created one of the largest, most advanced pipelines in the industry.

Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day

Retrieved on: 
Tuesday, December 15, 2020
Health, Diabetes, Infectious diseases, Genetics, Pharmaceutical, Optical, Biotechnology, Alnylam Pharmaceuticals, Therapeutic gene modulation, Companies, Biotechnology, LinkedIn, Life sciences, RNAi, Alnylam Pharmaceuticals

Five years ago, we charted our Alnylam 2020 goals of building a multi-product, global commercial company with a deep clinical pipeline for future growth and an organic product engine for sustainable innovation.

Key Points: 
  • Five years ago, we charted our Alnylam 2020 goals of building a multi-product, global commercial company with a deep clinical pipeline for future growth and an organic product engine for sustainable innovation.
  • Our annual R&D Day will feature updates across our pipeline, including deep dive discussions on RNAi therapeutic opportunities in wild-type ATTR amyloidosis, hypertension, and NASH.
  • Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development.
  • For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn .

ESCAPE Bio Appoints Edward Owens and Scott Morrison to Board of Directors

Retrieved on: 
Friday, December 11, 2020
Research, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Biotechnology, Alnylam Pharmaceuticals, Therapeutic gene modulation

ESCAPE Bio Inc., a clinical stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, announced that Edward Owens and Scott Morrison have been appointed to the Board of Directors.

Key Points: 
  • ESCAPE Bio Inc., a clinical stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, announced that Edward Owens and Scott Morrison have been appointed to the Board of Directors.
  • Mr. Owens is a retired partner of Wellington Management, where he was a portfolio manager and global industry analyst from 1974 to 2012.
  • Mr. Owens serves on the board of directors of Ironwood Pharmaceuticals and Stealth BioTherapeutics.
  • ESCAPE Bio is a clinical stage, privately held biopharmaceutical company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases.

Alnylam to Webcast Virtual R&D Day

Retrieved on: 
Tuesday, December 8, 2020
Research, Infectious diseases, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Biotechnology, Branches of biology, Biology, Alnylam Pharmaceuticals, Therapeutic gene modulation, RNA, RNA interference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Companys website, www.alnylam.com , on December 15 and 16, 2020.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Companys website, www.alnylam.com , on December 15 and 16, 2020.
  • Replays will be available on the Alnylam website within 48 hours after each event.
  • Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.
  • Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development.

Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO™ (lumasiran)

Retrieved on: 
Thursday, December 3, 2020
Life sciences, Biotechnology, Biology, Alnylam Pharmaceuticals, Therapeutic gene modulation, Specialty pharmacy, Lumasiran, Rare disease, Pharmacy

ELK GROVE VILLAGE, Ill., Dec. 3, 2020 /PRNewswire/ --Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Alnylam Pharmaceuticals as a limited distribution partner for OXLUMO (lumasiran).

Key Points: 
  • ELK GROVE VILLAGE, Ill., Dec. 3, 2020 /PRNewswire/ --Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Alnylam Pharmaceuticals as a limited distribution partner for OXLUMO (lumasiran).
  • It is estimated that PH1 affects one to three individuals per million in the United States and Europe.
  • "We are pleased to expand our partnership with Alnylam Pharmaceuticals and add OXLUMO to the therapies we provide for the treatment of ultra-rare genetic conditions," said Mike Fieri, Orsini Chief Executive Officer.
  • Providing patients with comprehensive and compassionate care since 1987, Orsini is a leading, independent specialty pharmacy focused on rare and ultra-rare diseases and gene therapies.

Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference

Retrieved on: 
Wednesday, December 2, 2020
Therapeutic gene modulation, Antisense RNA, Spinal muscular atrophy, Life sciences, Biology, Huntington's disease, Ionis Pharmaceuticals, Genetics, Ionis, Antisense therapy

CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtualfireside chat at the BMO 2020 Growth and ESGConference at 3:00 p.m. E.T.

Key Points: 
  • CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtualfireside chat at the BMO 2020 Growth and ESGConference at 3:00 p.m. E.T.
  • A webcast replay will be available for a limited time at the same address.
  • Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs.
  • To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.

Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference

Retrieved on: 
Wednesday, November 25, 2020
Biotechnology, Pharmaceutical, Genetics, Health, Biotechnology, Branches of biology, Biology, Alnylam Pharmaceuticals, Therapeutic gene modulation, RNA, RNA interference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 43rd Nasdaq Virtual Investor Conference on Friday, December 4, 2020 at 11:00 am ET.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 43rd Nasdaq Virtual Investor Conference on Friday, December 4, 2020 at 11:00 am ET.
  • A live audio webcast of the presentation will be available on the Investors section of the Companys website at www.alnylam.com/events .
  • A replay will be available on the Alnylam website within 48 hours after each event.
  • Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.